

# Amanda Leach

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5800908/publications.pdf>

Version: 2024-02-01

67  
papers

7,720  
citations

76294

40  
h-index

102432

66  
g-index

67  
all docs

67  
docs citations

67  
times ranked

5035  
citing authors

#	ARTICLE	IF	CITATIONS
1	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. <i>New England Journal of Medicine</i> , 2011, 365, 1863-1875.	13.9	773
2	Efficacy of the RTS,S/AS02A vaccine against <i>Plasmodium falciparum</i> infection and disease in young African children: randomised controlled trial. <i>Lancet, The</i> , 2004, 364, 1411-1420.	6.3	687
3	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. <i>New England Journal of Medicine</i> , 2012, 367, 2284-2295.	13.9	653
4	Duration of protection with RTS,S/AS02A malaria vaccine in prevention of <i>Plasmodium falciparum</i> disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. <i>Lancet, The</i> , 2005, 366, 2012-2018.	6.3	367
5	Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. <i>New England Journal of Medicine</i> , 2008, 359, 2521-2532.	13.9	365
6	Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. <i>New England Journal of Medicine</i> , 2016, 374, 2519-2529.	13.9	336
7	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. <i>New England Journal of Medicine</i> , 2015, 373, 2025-2037.	13.9	332
8	Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya. <i>PLoS ONE</i> , 2009, 4, e4708.	1.1	257
9	Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. <i>Lancet, The</i> , 2007, 370, 1543-1551.	6.3	244
10	Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure. <i>New England Journal of Medicine</i> , 2013, 368, 1111-1120.	13.9	240
11	Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. <i>Journal of Infectious Diseases</i> , 2020, 222, S577-S583.	1.9	231
12	From the circumsporozoite protein to the RTS,S/AS candidate vaccine. <i>Hum Vaccin</i> , 2010, 6, 90-96.	2.4	217
13	Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants. <i>New England Journal of Medicine</i> , 2008, 359, 2533-2544.	13.9	204
14	Towards an RTS,S-based, multi-stage, multi-antigen vaccine against <i>falciparum</i> malaria: progress at the Walter Reed Army Institute of Research. <i>Vaccine</i> , 2005, 23, 2243-2250.	1.7	174
15	Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. <i>Lancet Infectious Diseases, The</i> , 2011, 11, 102-109.	4.6	152
16	Safety and efficacy of the RTS,S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2011, 11, 741-749.	4.6	122
17	Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area. <i>PLoS ONE</i> , 2009, 4, e6465.	1.1	118
18	Long-Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children. <i>Journal of Infectious Diseases</i> , 2009, 200, 329-336.	1.9	117

#	ARTICLE	IF	CITATIONS
19	Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Controlled Trial. PLoS ONE, 2008, 3, e1465.	1.1	104
20	Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine, 2007, 25, 176-184.	1.7	90
21	Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatric Infectious Disease Journal, 1996, 15, 333-339.	1.1	89
22	Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria. PLoS ONE, 2011, 6, e25786.	1.1	89
23	A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine, 2006, 24, 2850-2859.	1.7	86
24	Safety and immunogenicity of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine, 2005, 23, 4148-4157.	1.7	84
25	A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon. PLoS ONE, 2009, 4, e7611.	1.1	78
26	Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine. Journal of Immunology, 2012, 188, 5054-5062.	0.4	77
27	Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children. PLoS ONE, 2009, 4, e5165.	1.1	77
28	A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatric Infectious Disease Journal, 1997, 16, 1135-1140.	1.1	74
29	Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children. PLoS ONE, 2009, 4, e7302.	1.1	73
30	RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection. PLOS Clinical Trials, 2006, 1, e5.	3.5	70
31	Evaluation of the Safety and Immunogenicity of the RTS,S/AS01E Malaria Candidate Vaccine When Integrated in the Expanded Program of Immunization. Journal of Infectious Diseases, 2010, 202, 1076-1087.	1.9	64
32	Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. PLOS Clinical Trials, 2006, 1, e34.	3.5	64
33	Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children. Journal of Infectious Diseases, 2011, 204, 9-18.	1.9	60
34	Association Between Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection in Early Life and Recurrent Wheeze and Asthma in Later Childhood. Journal of Infectious Diseases, 2020, 222, S628-S633.	1.9	60
35	Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children. PLOS Clinical Trials, 2006, 1, e32.	3.5	59
36	Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malaria Journal, 2011, 10, 224.	0.8	58

#	ARTICLE	IF	CITATIONS
37	Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE, 2010, 5, e9041.	1.1	54
38	Impact of RTS,S/AS02A and RTS,S/AS01B on Genotypes of <i>P. falciparum</i> in Adults Participating in a Malaria Vaccine Clinical Trial. PLoS ONE, 2009, 4, e7849.	1.1	50
39	Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Human Vaccines and Immunotherapeutics, 2019, 15, 2386-2398.	1.4	48
40	A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis. Journal of Infectious Diseases, 2020, 222, S672-S679.	1.9	47
41	Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial. Vaccine, 2011, 29, 6059-6067.	1.7	44
42	Development of the RTS,S/AS malaria candidate vaccine. Vaccine, 2009, 27, G67-G71.	1.7	40
43	Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region. Malaria Journal, 2013, 12, 11.	0.8	39
44	Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial. PLoS ONE, 2010, 5, e13838.	1.1	38
45	Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial. Trials, 2007, 8, 11.	0.7	34
46	Five year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum Vaccin, 2009, 5, 242-247.	2.4	32
47	Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. Malaria Journal, 2011, 10, 221.	0.8	29
48	A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants. Parasite Immunology, 1995, 17, 441-444.	0.7	28
49	Effects of misclassification of causes of death on the power of a trial to assess the efficacy of a pneumococcal conjugate vaccine in The Gambia. International Journal of Epidemiology, 2003, 32, 430-436.	0.9	27
50	Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children. Malaria Journal, 2011, 10, 222.	0.8	27
51	Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial. Lancet Infectious Diseases, The, 2016, 16, 1134-1144.	4.6	26
52	Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infections in Children With Bronchopulmonary Dysplasia: Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2020, 222, S620-S627.	1.9	25
53	Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine, 2008, 26, 174-184.	1.7	24
54	Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children. PLoS ONE, 2010, 5, e14090.	1.1	23

#	ARTICLE	IF	CITATIONS
55	Causes of mortality in twins in a rural region of The Gambia, West Africa. <i>Annals of Tropical Paediatrics</i> , 1998, 18, 231-238.	1.0	22
56	Preparation for a pneumococcal vaccine trial in The Gambia: individual or community randomisation?. <i>Vaccine</i> , 1999, 18, 633-640.	1.7	20
57	Season of birth is not associated with delayed childhood mortality in Upper River Division, The Gambia. <i>Tropical Medicine and International Health</i> , 2000, 5, 628-632.	1.0	16
58	Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66. <i>Parasite Immunology</i> , 1997, 19, 579-581.	0.7	14
59	Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1489-1500.	1.4	14
60	Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 483-491.	1.1	13
61	Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials. <i>Hum Vaccin</i> , 2011, 7, 1309-1316.	2.4	10
62	Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: A randomized, double-blind, lot-to-lot consistency trial. <i>Vaccine</i> , 2014, 32, 6556-6562.	1.7	7
63	Antigenuria in gambian infants following immunization with a Haemophilus influenzae type b polyribosylribitol phosphate-tetanus toxoid protein conjugate (PRP-T) vaccine. <i>Diagnostic Microbiology and Infectious Disease</i> , 1998, 32, 15-19.	0.8	6
64	Low Sensitivity of BinaxNOW RSV in Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, S640-S647.	1.9	6
65	Use of pneumococcal polysaccharide vaccine in children. <i>Lancet</i> , The, 1998, 352, 575.	6.3	5
66	Development of the RTS,S/AS Vaccine Candidate from Concept to Phase III. , 2011, , 121-133.		4
67	Response to "Poor control vaccines in two randomised trials of malaria vaccine". <i>Vaccine</i> , 2009, 27, 4745-4746.	1.7	3